SCHEMBL846943

SCHEMBL846943

O=Cc1ccc(SCCO)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA7 P43166 1/20 0.52
CA13 Q8N1Q1 1/20 0.52
ALDH1A1 P00352 9/20 0.48
ALDH5A1 P51649 1/20 0.43
ABAT P80404 1/20 0.43
HPGD P15428 5/20 0.41
MAPT P10636 4/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
KDM4E B2RXH2 4/20 0.40
TDP1 Q9NUW8 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HSD17B10 Q99714 2/20 0.38
CYP2A6 P11509 1/20 0.38
MEN1 O00255 1/20 0.37
APAF1 O14727 1/20 0.37
MAP2K7 O14733 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL15643622 0.89 CDC25A (0.44) CA2CA12CA1CA7CA13
SCHEMBL8637757 0.82 CA2 (0.61) CA2CA12CA1CA7CA13
SCHEMBL1025762 0.79 CA2 (0.47) CA2CA12CA1CA7CA13
SCHEMBL2916575 0.79 ALDH1A1 (0.48) ALDH1A1ALDH5A1ABATHPGDMAPT
SCHEMBL8595279 0.79 ALDH1A1 (0.54) CA2CA12CA1CA7CA13
SCHEMBL11170850 0.79 ALDH1A1 (0.50) ALDH1A1ALDH5A1ABATHPGDMAPT
SCHEMBL1246027 0.77 UNG (0.42) CA2CA12CA1CA7CA13
SCHEMBL3405047 0.76 ALDH1A1 (0.50) CA2CA12CA1CA7CA13
SCHEMBL3900894 0.75 CA2 (0.55) CA2CA12CA1CA7CA13
SCHEMBL8529367 0.75 CA2 (0.55) CA2CA12CA1CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132298-A1 A METHOD FOR PRODUCING INTERFERENCE ELEMENTS BASF SE (DE) 2026-05-14 US disclosed
EP-4709544-A1 COMPOSITIONS, COMPRISING SILVER NANOPLATELETS BASF SE (DE) 2026-03-18 EP disclosed
US-12515253-B2 Compositions, comprising silver nanoplatelets BASF SE (DE) 2026-01-06 US disclosed
US-20250263566-A1 CASTING LACQUER FOR SCREEN PRINTING DE LA RUE INTERNATIONAL LIMITED (GB) 2025-08-21 US disclosed
US-12325806-B2 Photocurable composition for use in 3D printing BASF SE (DE) 2025-06-10 US disclosed
US-12296391-B2 Security element BASF SE (DE) 2025-05-13 US disclosed
EP-4337734-B1 COMPOSITIONS, COMPRISING PLATELET-SHAPED TRANSITION METAL PARTICLES BASF SE (DE) 2025-04-23 EP disclosed
US-12208447-B2 Compositions, comprising silver nanoplatelets BASF SE (DE) 2025-01-28 US disclosed
EP-4490577-A1 CASTING LACQUER FOR SCREEN PRINTING BASF SE (DE) 2025-01-15 EP disclosed
WO-2024231418-A1 COMPOSITIONS, COMPRISING SILVER NANOPLATELETS BASF SE (DE) 2024-11-14 WO disclosed
WO-2005064008-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-07-14 WO disclosed
EP-1509537-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2005-03-02 EP disclosed
WO-2003090690-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed
EP-0570780-B1 Chloroethylsulphonylbenzaldehydes BASF AG (DE) 1996-03-06 EP disclosed
US-5493057-A INTERMEDIATES FOR REACTIVE DYES BASF AKTIENGESELLSCHAFT (DE) 1996-02-20 US disclosed
EP-0570780-A1 Chloroethylsulphonylbenzaldehydes BASF Aktiengesellschaft (DE) 1993-11-24 EP disclosed
EP-0309839-B1 PROCESS FOR THE PREPARATION OF OXYETHYL MERCAPTOBENZALDEHYDES, AND THEIR OXIDATION PRODUCTS HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-04 EP disclosed
US-4922014-A Process for the preparation of oxethylmercaptobenzaldehydes and their oxidation products HOECHST AKTIENGESELLSCHAFT (DE) 1990-05-01 US disclosed
EP-0309839-A1 Process for the preparation of oxyethyl mercaptobenzaldehydes, and their oxidation products HOECHST AKTIENGESELLSCHAFT (DE) 1989-04-05 EP disclosed
EP-0089154-A2 Ethanolamine derivatives, their preparation and use in pharmaceutical compositions BEECHAM GROUP PLC (GB) 1983-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132298-A1 A METHOD FOR PRODUCING INTERFERENCE ELEMENTS COPE, COPB2, C9 CA2 1824/4885CA12 214/4885CA1 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.